Matribhumi Samachar English
Vancouver, British Columbia and San Francisco, California–(Newsfile Corp. – July 6, 2026) – InMed Pharmaceuticals, Inc. (NASDAQ: INM) (“InMed” or the “Company”) today announced that it has entered into an amendment (the “Amendment”) to the previously announced definitive merger agreement (the “Agreement”) for an all-stock transaction with Mentari Therapeutics, Inc. …
Read More »InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia–(Newsfile Corp. – May 6, 2026) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company“), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2026 …
Read More »InMed Provides Update on Pharmaceutical Development Programs – Advancing Lead Drug Candidates Towards IND and Clinical Trial
Advancing Alzheimer’s and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities Targeting Initiation of Phase 1 Clinical Trial in Alzheimer’s Disease in 2027 Vancouver, British Columbia–(Newsfile Corp. – March 9, 2026) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company“), a pharmaceutical company focused on developing a …
Read More »InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
Vancouver, British Columbia–(Newsfile Corp. – March 6, 2026) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company“), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors, today announced an update regarding BayMedica LLC (“BayMedica“), a wholly owned subsidiary of the …
Read More »